# Basgenbio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/basgenbio-co

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.basgenbio.com
- Total disclosed funding: $5.4M
- Latest round: Series A (Apr 20, 2021)
- Investors on record: 1

## About

Based in Seoul, South Korea, and founded in 2018, Basgenbio Co. Ltd operates as a biotechnology company that offers biotechnology company that provides its clients with preventive and precision medicine services. In June 2023, Basgenbio Co., Ltd. raised KRW 3 billion in series B funding led by Celltrion. As of 2023, the company is led by its CEO Tae Jang.

The biotechnology company provides its clients with preventive and precision medicine services based on bio cohort big data and artificial intelligence technology. The firm offers the COCD Platform (Clinico-Omics Cohort Database) that integrates global biobank data on K-Biobank. BasGenBio operates various global biobanks on its own COCD* platform.

The company plans to use the June 2023 funding to obtain more genome cohort data and R&D.

## Funding rounds

- Series A, Apr 20, 2021, $5.4M — NH Investment & Securities

## Investors

- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series A